BioSpace News Archive

VBL Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the third quarter of the year and provided recent business highlights.

UroGen Pharma Ltd. today announced financial results for the third quarter ended September 30, 2021, and provided an overview of the Company’s recent developments.

Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments.

Sonoma Pharmaceuticals, Inc. today announced financial results for its second fiscal quarter and six months ended September 30, 2021.

Celcuity Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to provide Ibrance (palbociclib) for use in Celcuity’s Phase 3 clinical trial at no cost to Celcuity.

Shanghai Junshi Biosciences Co. and Coherus Biosciences, Inc. announced today that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (ODD) for toripalimab for the treatment of esophageal cancer.

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced that the Food and Drug Administration (FDA) has granted the Company De Novo clearance for the Hemolung Respiratory Assist System.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of adult and pediatric patients with rare cancers, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced its financial results for the third quarter and nine months ended September 30, 2021.

The iQ Group Global Ltd (iQG Ltd) (NSX:IQG) on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), has announced the successful completion of a clinical validation study showcasing the efficacy of its rapid SARS-Cov-2 Antibody test.